Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
Sherif Ibrahim(Cairo University), Martin Götte(University of Münster)
Cited by 276
Related Papers
Syndecan-1 (CD138) Modulates Triple-Negative Breast Cancer Stem Cell Properties via Regulation of LRP-6 and IL-6-Mediated STAT3 Signaling
|PLoS ONE|2013|117
<i>HS3ST2</i> modulates breast cancer cell invasiveness via MAP kinase‐ and Tcf4 (Tcf7l2)‐dependent regulation of protease and cadherin expression
|International Journal of Cancer|2014|72
Role of the Heparan Sulfate Proteoglycan Syndecan-1 (CD138) in Delayed-Type Hypersensitivity
|The Journal of Immunology|2009|59